WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201000
CAS#: 19262-68-1 (HCl)
Description: Dexmethylphenidate (also known as d-threo-methylphenidate (D-TMP), is the dextrorotatory enantiomer of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and releasing agent and thus a psychostimulant, which affects the CNS. Dexmethylphenidate is sold as Focalin by Novartis, as Attenade by Celgene and as a generic drug by Teva. Dexmethylphenidate is currently tested in the treatment of fatigue and nervous system side effects caused by chemotherapy. (Source: http://en.wikipedia.org/wiki/Dexmethylphenidate).
MedKoo Cat#: 201000
Name: Dexmethylphenidate HCl
CAS#: 19262-68-1 (HCl)
Chemical Formula: C14H20ClNO2
Molecular Weight: 269.77
Elemental Analysis: C, 62.33; H, 7.47; Cl, 13.14; N, 5.19; O, 11.86
Dexmethylphenidate is not available at this moment (controlled substance).
Related CAS #: 40431-64-9 (free base) 19262-68-1 (HCl)
Synonym: Focalin; DTMP.
IUPAC/Chemical Name: (R)-methyl 2-phenyl-2-((R)-piperidin-2-yl)acetate hydrochloride
InChi Key: JUMYIBMBTDDLNG-OJERSXHUSA-N
InChi Code: InChI=1S/C14H19NO2.ClH/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12;/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3;1H/t12-,13-;/m1./s1
SMILES Code: O=C(OC)[C@H](C1=CC=CC=C1)[C@@H]2NCCCC2.[H]Cl
The following data is based on the product molecular weight 269.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Moraska AR, Sood A, Dakhil SR, Sloan JA, Barton D, Atherton PJ, Suh JJ, Griffin PC, Johnson DB, Ali A, Silberstein PT, Duane SF, Loprinzi CL. Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Long-Acting Methylphenidate for Cancer-Related Fatigue: North Central Cancer Treatment Group NCCTG-N05C7 Trial. J Clin Oncol. 2010 Jul 12. [Epub ahead of print] PubMed PMID: 20625123.
2: Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010 Jul 7;7:CD006704. Review. PubMed PMID: 20614448.
3: Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Jul 7. [Epub ahead of print] PubMed PMID: 20607239.
4: Elie D, Gagnon P, Gagnon B, GiguÃ¨re A. [Using psychostimulants in end-of-life patients with hypoactive delirium and cognitive disorders: A literature review]. Can J Psychiatry. 2010 Jun;55(6):386-93. French. PubMed PMID: 20540834.
5: Goldstein S. Chronic Ritalin use and cancer. J Atten Disord. 2010 Mar;13(5):441. PubMed PMID: 20190147.
6: Walitza S, KÃ¤mpf K, Oli RG, Warnke A, Gerlach M, Stopper H. Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. Toxicol Lett. 2010 Mar 1;193(1):4-8. Epub 2009 Dec 22. Review. PubMed PMID: 20026394.
7: Johnson RL, Block I, Gold MA, Markwell S, Zupancic M. Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology. 2009 Nov 16. [Epub ahead of print] PubMed PMID: 19918954.
8: Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009 Nov;38(5):650-62. PubMed PMID: 19896571.
9: Escalante CP, Manzullo EF. Cancer-related fatigue: the approach and treatment. J Gen Intern Med. 2009 Nov;24 Suppl 2:S412-6. PubMed PMID: 19838841; PubMed Central PMCID: PMC2763160.
10: Schwartz AL. Fatigue in long-term cancer survivors. Oncology (Williston Park). 2009 Jul;23(8 Suppl):27, 33-4. Review. PubMed PMID: 19860040.
Dexmethylphenidate (trade name Focalin, Novartis, generic by Teva also available), otherwise known as d-threo-methylphenidate (D-TMP), is the dextrorotatory enantiomer of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant, which affects the CNS.
Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. It is proposed that stimulants help ameliorate the symptoms of ADHD by making it easier for the user to concentrate, avoid distraction, and control behavior. Dexmethylphenidate may also improve listening skills and organization of tasks, and may help prevent tic disorders. Because it is a psychostimulant, dexmethylphenidate may also help with narcolepsy and in certain cases of major depression. Although its has many beneficial effects, because it is a stimulant there is a considerable chance for abuse of the drug and intake should be closely monitored by you and your doctor. Importantly, the propensity for "abuse" with d-TMP is much less than for the corresponding racemic product.